CHERRY HILL, N.J., April 29 /PRNewswire-FirstCall/ --Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company, today announced that it will advance the release of Citroxin to domestic and international health agencies including hospitals, clinics, and medical offices as well as other at risk institutions and companies, such as schools and airlines. Nuvilex has proof of Citroxin's effectiveness in eliminating swine influenza virus (SIV; H1N1 subtype) and avian influenza virus (AIV; H9N9 subtype) on surface areas but has not yet submitted Citroxin for EPA approval as an antiviral agent. Citroxin samples will be provided at no cost and the Company will provide technical assistance. Citroxin is being released early as the current Swine Flu outbreak requires the best products be deployed to combat the growing epidemic.
Independent laboratory testing of Citroxin showed a 100% kill rate for the "big six" bacterial health threats, including E. coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, Streptococcus, and Black Mold. Citroxin is an EPA registered germicidal composition (EPA registration number 82723-1) and is patented in the US and world wide (US 7,439,218 and WIPO 2007/038265 A3).
Interested parties should contact A. Peter Morello III, Ph.D., Director of Research at Nuvilex via a specially set up email address: email@example.com for product information and specifications as well as to request a sample.
"Given the seriousness of the threat of the spread of swine flu, we believe it is our duty to push hard to make Citroxin available as soon as possible," said Martin E. Schmieg, Chairman and CEO of Nuvilex, Inc. "Much of the innovation in science and technology for combating big problems comes from small companies such as Nuvilex. Moving our discoveries into the world takes resources - investment capital, which has all but disappeared from the market because of the current economic downturn. If Citroxin takes root as envisioned, demand will outpace our manufacturing capabilities and it will be necessary for us to seek a commercial partner to move the product quickly into the marketplace."
Citroxin is a eco-friendly surface cleaner. The Company's viral testing to date has been led by Sagar M. Goyal, D.V.M., Ph.D. at the
The Company, in conjunction with international based academic researchers, has also treated H9N9 AIV with Citroxin. In the AIV H9N9 experiments, Citroxin also served as a better virucidal agent when it received a smaller viral challenge (1000, 100, and 10 tissue culture infectious dose50, or TCID50, of virus).
"Although Citroxin is not yet proven to be immunogenic, experiments do suggest that Citroxin can serve as an effective cleaner or disinfectant for surfaces that may have come into contact with SIV, AIV, or other types of virus particles," said Dr. Morello. "We are ready, willing and able to help the global public health community in combating the swine flu outbreak."
About Nuvilex, Inc.
Nuvilex, formerly eFoodSafety.com, Inc. is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Investor Relations Contacts: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: firstname.lastname@example.org Amy Glynn The Ruth Group Ph: 646-536-7023 Email: email@example.com Press Contact: Pat Arcand Arcand & Madison Public Relations Ph: 617-576-7777 Email: firstname.lastname@example.org
|SOURCE Nuvilex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved